The aim of this study was to investigate if 2 common single nucleotide polymorphisms (SNPs) in the interleukin-13 (IL-13) gene, rs1800925 and rs20541 are associated with chronic obstructive pulmonary disease (COPD) risk.
Introduction
Chronic obstructive pulmonary disease (COPD) is a common, chronic inflammatory airway disease characterized by irreversible airflow obstruction. It is a leading cause of death worldwide and currently available treatments are largely ineffective. [1] Although exposure to cigarette smoke is the greatest risk factor for COPD, other environmental and genetic factors are likely involved. Familial aggregation studies and genome-wide association studies have suggested a strong genetic component to the risk of developing COPD. [2] Interleukin-13 (IL-13) is a pleiotropic cytokine whose primary source are activated type 2 T helper (Th2) cells and to a lesser extent mast cells, macrophages, dendritic cells, and natural killer cells. IL-13 has a variety of functions, including regulation of proinflammatory cytokine expression from macrophages, upregulation of adhesion molecules, induction of B-cell production of immunoglobulin E (IgE), and effects on mucus synthesis. [3] Animal and clinical studies have indicated that IL-13 may be involved in the pathogenesis of COPD. Zheng and coworkers [4] reported that IL-13 overexpression in the adult murine lung resulted in emphysema with enhanced lung volumes and compliance, mucus metaplasia, and inflammation. In patients with emphysema, lung IL-13 expression was positively correlated with pulmonary function including lung distension, airway obstruction, and impaired gas exchange. [5] Moreover, there was an increasing number of IL-13-expressing cells in the bronchial submucosa of smokers with symptoms of chronic bronchitis, suggesting that IL-13 contributed to the hypersecretion of mucus. [6] Given the pivotal role of IL-13 in airways disease, the IL-13 gene was considered as a candidate gene for COPD susceptibility. Located on chromosome 5q31-33, the IL-13 gene has 2 common single-nucleotide polymorphisms (SNPs): the polymorphism rs1800925 is a C to T substitution in the 5 0 promoter region (-1055C/T), whereas rs20541 is a G to A exchange in exon 4. [7] Multiple association studies have evaluated the relationship of these genetic variations with COPD. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] However, previous research findings have been inconsistent and the contribution of these SNPs to COPD risk remains unclear. This meta-analysis aimed to evaluate the evidence for associations of rs1800925 and rs20541 with COPD risk.
Methods

Literature search strategy and selection of studies
A systematic search was conducted in accordance with recognized methods. We identified eligible studies by searching Scopus, Pubmed, ISI Web of Science, China National Knowledge Infrastructure (CNKI), and Wanfang databases for studies published before 8 May 2017. The search words were broad and included "chronic obstructive pulmonary disease," "COPD," "polymorphism," "variant," "genetics," "risk," "association," "rs1800925," "-1111C/T," "-1112C/T," "-1055," "rs20541," "R130Q," and "G2044A." There was no language restriction for the search. Two reviewers screened titles and abstracts to select potentially relevant studies. If the suitability of a paper was uncertain, the full text was reviewed. Reference lists of the included studies and previously published related meta-analyses were hand-searched to ensure that no relevant studies were missed. This meta-analysis conformed to the Meta-analysis of Observational Studies in Epidemiology (MOOSE) statement standards. Since we only used published data, we did not apply for ethics approval.
Any study was considered to be eligible for inclusion in our meta-analysis if it met the following criteria: published in a peerreviewed journal, assessing the association of rs1800925 and/or rs20541 with COPD risk, case-control design, published in English or Chinese, and reported data for genotypic or allelic frequency in both cases and controls.
Data extraction
Data from included studies were extracted by 2 reviewers using a data extraction form. Inconsistencies were resolved in a consensus meeting. The following variables were obtained: first author, country, year of publication, ethnicity of participants, number of COPD patients and control subjects, and HardyWeinberg equilibrium (HWE; calculated, when not reported). We did not contact authors to obtain additional data.
Quality assessment
Methodological quality was assessed by 2 reviewers using the Newcastle-Ottawa Scale (http://www.ohri.ca/programs/clinica l_epidemiology/oxford.asp). Disagreements were resolved by consensus.
Statistical analyses
We calculated unadjusted odds ratios (ORs) with the corresponding 95% confidence interval (95% CI) from raw genotype frequency data and combined these for meta-analysis. According to the Single Nucleotide Polymorphism database (http://www.ncbi. nlm.nih.gov/snp), the minor allele is the T in rs1800925, while it is the A allele in rs20541. The Z-test was used to calculate the P-value of the overall effect for the meta-analysis and P <.05 was considered as statistically significant. Forest plots were used to display OR and 95% CI for each study and the pooled summary effect. Between-study heterogeneity was assessed by the Q-statistic and was considered statistically significant at P <. 10 . In case of high between-study heterogeneity, the DerSimonian-Laird random effects model is the model of choice to calculate the pooled effect size, [18] rather than the fixed-effects model. HWE was assessed for each dataset using the x 2 goodness-of-fit test. Sensitivity analysis involving omission of 1 study at a time and recalculating the pooled OR was conducted to test for robustness of the pooled effects. Publication bias was evaluated with the Begg rank correlation test (Begg test). Since there were fewer than 10 studies qualified for each SNP, We did not perform funnel plots to evaluate publication bias. [19] Stata software version 11.0 was used for all statistical analyses. P values <.05 were considered statistically significant for all tests, except for Q test for heterogeneity.
Results
Literature search and studies' characteristics
The literature search in Scopus, PubMed, ISI Web of Science, CNKI, and Wanfang databases yielded 632 records, and 1 study was identified through lists of references (Fig. 1 ). After screening of the abstracts of these studies, 619 duplicate and/or irrelevant studies were removed. The remaining studies were retrieved for full-text evaluations. Among these, 11 studies from 10 papers met the inclusion criteria and were included in the meta-analysis. These studies were published in a relatively limited time span (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) , witnessing the recent interest in this field. The polymorphisms rs1800925 and rs20541 were in HWE for all studies. The characteristics of the individual studies included in the meta-analysis are provided in Tables 1 and 2 .
Association of rs1800925 with COPD
Nine studies from 8 papers containing 1477 cases and 891 controls investigated the association between rs1800925 and COPD risk. In terms of ethnicity, 4 studies with 922 COPD patients and 347 controls assessed the SNP in Caucasians, [8, 10, 12, 15] whereas 5 studies including 555 cases and 544 controls investigated rs1800925 in Asians. [9] [10] [11] 13, 17] In each study, 4 ORs and their corresponding 95% CIs were calculated: OR T allele versus C allele; dominant OR (TT + CT versus CC); recessive OR (TT versus CT + CC); and additive OR (TT versus CT versus CC). The pooled analysis showed that the T allele of rs1800925 was associated with increased risk of COPD in the overall population (Caucasians and Asians) (OR = 1.57, 95% CI: 1.21-2.04, P z = .001) ( Fig. 2 and Table 3 ), and this association was statistically significant under dominant (OR = 1.58, 95% CI: 1.19-2.10, P z = .002), recessive (OR = 2.49, 95% CI: 1.59-3.88, P z <.001) and additive (OR = 2.39, 95% CI: 1.50-3.81, P z <.001) models of the genotype (Table 3) . We further performed subgroup analysis based on ethnicity, finding that the T allele of rs1800925 was associated with increased risk of COPD in Asians (OR = 1.88, 95% CI: 1.23-2.87, P z = .004) and Caucasians (OR = 1.30, 95% CI: 1.01-1.67, P z = .041), respectively ( Fig. 2 and Table 3 ). Compared to all studies together, between-study heterogeneity was reduced in Caucasians (P h = .185 for dominant model and P h = .314 for allelic contrast) but not in Asians (P h = .059 for dominant model and P h = .016 for allelic contrast) ( Table 3 ). The results of Begg test were not significant, suggesting no evidence of publication bias (Table 3) . Sensitivity analysis did not appreciably change the results of our meta-analyses (Fig. 3) .
Association between rs20541 and COPD risk
Seven studies from 6 papers with a total of 1418 COPD patients and 763 control subjects were included in the Medicine meta-analysis for rs20541. [8] [9] [10] 12, 14, 16] In each study, 4 ORs and their corresponding 95% CIs were calculated: OR A allele versus G allele; dominant OR (AA + AG versus GG); recessive OR (AA versus AG + GG); and additive OR (AA versus AG versus GG). In the primary pooled analysis, we found no association between this polymorphism and COPD risk with all eligible studies (Caucasians and Asians) under dominant (OR = 1.12, 95% CI: 0.93-1.34, P z = .251), recessive (OR = 1.26, 95% CI: 0.87-1.83, P z = .221), and additive (OR = 1.30, 95% CI: 0.86-1.96, P z = .208) models (Table 4 ). In addition, we did not find associations in allele contrast (OR = 1.12, 95% CI: 0.96-1.30, P z = .152) (Table 4 ). However, in subgroup analysis according to ethnicity, we found that rs20541 was associated with COPD risk in Caucasians under the recessive model (OR = 2.79, 95% CI: 1.13-6.92, P z = .026), whereas this SNP was not associated with COPD in Asians (Table 4 ). Sensitivity analysis demonstrated that omission of 1 study did not significantly influence the summary ORs (Fig. 3) . We did not find between-study heterogeneity in any of the genetic risk models (Table 4) . We did not identify publication bias for this SNP (Table 4 ).
Discussion
In the literature, there were apparently conflicting associations reported between polymorphisms of the IL-13 gene and COPD risk. This study combined data from studies from Caucasian and Asian populations to investigate the relationship of 2 common IL-13 SNPs, rs1800925 and rs20541, with COPD. The main findings of our meta-analysis are the following: (1) the T allele of rs1800925 is associated increased risk of COPD in both Caucasians and Asians. In Asians, this was confirmed for dominant (TT + CT vs CC), recessive (TT vs CT + CC), and additive (TT vs CT vs CC) models, (2) and rs20541 is associated with increased risk of COPD in Caucasians under the recessive model (AA vs GA + GG), whereas there is no association of rs20541 with COPD risk in Asians.
IL-13 is a multifunctional cytokine which exerts important effects on both inflammatory and structural cells within the airway. It was observed that cells expressing IL-13 dramatically increased in the bronchial submucosa of smokers with symptoms of chronic bronchitis.
[6] IL-13 induced mucus production in human airway epithelial cells through chloride channel calciumactivated 1-mediated activation of mitogen-activated protein kinase 13. [20] It also stimulated human bronchial epithelial cells to release proinflammatory cytokine IL-8, which played an important role in attracting neutrophils and monocytes in airway inflammation. [21] In addition, IL-13 enhanced monocyte-derived macrophages' expression of osteopontin, a phosphorylated acidic glycoprotein that correlated with the degree of airflow limitation in smokers. [22] In vivo studies showed that the overexpression of IL-13 in the adult murine lung caused a phenotype that mirrored human COPD with prominent emphysema. [4] These lines of evidence suggested that IL-13 was implicated in the pathogenesis of COPD and genetic variations in the IL-13 gene may modify the risk for developing COPD. In this meta-analysis, we found an association of rs1800925 and rs20541 with COPD. The polymorphism rs1800925 is located in the promoter region of the IL-13 gene, which results in enhanced promoter activity and increased IL-13 transcription. [23] Previous studies demonstrated that rs1800925 enhanced the adverse effect of cigarette smoking on lung function, leading to the development of COPD. [24] The SNP rs20541 in exon 4 leads to the nonconservative replacement of a arginine with a glutamine in a-helix D, the region critical for interactions between IL-13 and its receptors. [25] Compared to wild-type (WT) IL-13, rs20541 was shown to be associated with higher IL-13 activity. Structure/function analyses found that rs20541 was significantly more active than WT IL-13 in inducing signal transducer and activator of transcription 6 www.md-journal.com Table 1 Characteristics of the studies of rs1800925 and COPD risk. Table 2 Characteristics of the studies of rs20541 and COPD risk. phosphorylation, an essential step in the IL-13-dependent regulation of gene expression in inflammatory cells. [26] Carriers of the A allele of rs20541 were associated with lower lung function measured by forced expiratory volume in 1 second (FEV 1 ). [12] Therefore, the adverse effects mediated by rs1800925 and rs20541 may increase the risk of developing COPD in individuals under certain environmental conditions. For rs20541, we noticed that the association with COPD was different between Caucasians and Asians. Several reasons may account for this difference. First, Caucasians and Asians have different genetic background. The minor allele frequencies of rs20541 in control subjects from Caucasian studies and Asian studies were 0.171 (95% CI: 0.144-0.202) and 0.295 (95% CI: 0.266-0.326), respectively. Second, COPD is a complex disease affected by interactions between genetic, epigenetic, and environmental factors. These factors may modify COPD risk in a distinct way in different populations.
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Our results contrasted with those of a prior meta-analysis on the role of rs1800925 in COPD, finding that the T allele was not associated with increased risk of COPD in Asians. [27] We Figure 2 . Meta-analysis of the association between rs1800925 and COPD risk in allele contrast (T allele vs C allele). Table 3 Meta-analysis of the association between rs1800925 and COPD risk. .314 NA CI = confidence interval, COPD = chronic obstructive pulmonary disease, NA = not applicable, OR = odds ratio, P B = P value for Begg test, P h = P value for heterogeneity, P z = P value for overall effect.
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noticed that the prior meta-analysis included an Asian study showing deviation from HWE in the pooled analysis, [28] but it missed a qualified Asian study published in 2004 [9] which we included in our meta-analysis. In addition, the genotype distribution of rs1800925 was not correctly extracted from a case-control association study [12] in the prior meta-analysis. Besides these discrepancies, we included a recently published Asian study which provided new dataset for rs1800925. [17] Thus, the results of our analyses were more reliable to some extent. The IL-13 gene is located on chromosome 5q31-33 in the cluster of genes encoding Th2 cytokines. It has been reported that there is strong linkage disequilibrium (LD) between IL-13 SNPs, [29] which makes it difficult to identify the true genetic variation for COPD. Since most included studies did not perform haplotype analysis for the IL-13 polymorphisms, we were unable to address this issue in this meta-analysis. It will be extremely helpful to evaluate the relationship of COPD with haplotypes constructed by rs1800925 and rs20541 in large populations.
There are several limitations to consider when interpreting the results of this meta-analysis. First, although we identified 9 studies for rs1800925 and 7 studies for rs20541 through extensive literature search from 5 major databases, the total number of subjects was still small. We expect that as more studies become available, a more comprehensive evaluation of the association of rs1800925 and rs20541 with COPD risk will be performed in the future. Second, the relationship of other IL-13 polymorphisms with COPD was assessed in prior studies, such as rs1295685 and rs1881457. [17] However, because the number of eligible studies was <3, we could not perform pooled analyses for these SNPs. Third, Asian studies evaluating rs1800925 showed between-study heterogeneity, which may be attributable to discrepancies in diagnostic criteria for COPD, selection of control subjects, sample size, and genotyping method. Fourth, we did not account for other factors including age, sex, and exposure to cigarette smoke in the pooled analyses, because we did not obtain original data from all included studies. Table 4 Meta-analysis of the association between rs20541 and COPD risk.
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Test of publication bias .571 NA CI = confidence interval, COPD = chronic obstructive pulmonary disease, NA = not applicable, OR = odds ratio, P B = P value for Begg test, P h = P value for heterogeneity, P z = P value for overall effect. In conclusion, our meta-analysis indicates that the T allele of the IL-13 polymorphism rs1800925 is associated with increased risk of COPD in both Caucasians and Asians, whereas rs20541 is associated with COPD risk in Caucasians but not in Asians.
